The Biden administration announced new proposed guidance on Thursday that creates the possibility for the federal government to seize patents from drug companies if their prices are not deemed low enough.
The Department of Commerce and the Health and Human Services Department released a proposed framework for executive agencies that gives guidelines to confiscate patents from pharmaceutical companies if those protected products’ prices are too high and received funding from the federal government, according to an announcement from the White House. The move follows a push by President Joe Biden to decrease drug prices, with the administration releasing a list of 10 drugs in August that will be subject to price negotiations at the threat of up to a 95% tax levied on the companies that do not cooperate. (RELATED: FDA Inspections Of Foreign Drug Facilities Plummeted Since Before COVID-19, Study Shows)
“Today, the Biden-Harris Administration is announcing new actions to promote competition in health care and support lowering prescription drug costs for American families, including the release of a proposed framework for agencies on the exercise of march-in rights on taxpayer-funded drugs and other inventions, which specifies that price can be a factor in considering whether a drug is accessible to the public,” the release reads.
The Biden administration has, so far, restricted the guidance to only drugs that received taxpayer funding, noting that the industry has received billions of dollars for research and development on new prescription drugs, according to the announcement. The guidance invokes the Bayh-Dole Act, which grants march-in authority to the federal government to license the invention of private companies that received federal funding.
Folks, right now, 25 of the largest pharmaceutical companies in America control 70% of the market. This lack of competition drives up prices – making it harder for hardworking American families to access the health care they need.
Today, my Administration is doing something… pic.twitter.com/nvUQOIto3u
— President Biden (@POTUS) December 7, 2023
Biden has increasingly used executive power to interfere in the economy, often using the Cold War-era Defense Production Act, which gives the president authority over domestic industries necessary for the national defense. The president has used the act a number of times to promote industries related to the green energy transition, as well as to interfere in the artificial intelligence and rare earth mineral mining sectors.
Biden has been critical of the pharmaceutical industry, blaming high prices on a lack of competition and price gouging, according to a statement on X, formerly Twitter. He pointed to 25 of the largest pharmaceutical companies in the U.S. controlling around 70% of the market.
I believe if taxpayers fund the development of a new medicine, they ought to be able to afford it.
That’s what today’s action is all about. pic.twitter.com/RSDudmc20A
— President Biden (@POTUS) December 7, 2023
Just this year, premiums on family health insurance coverage in workplace plans have increased by 7% as of October, while wages only grew by 5.2% in that same time period. The changes follow a bout of inflation that has driven up prices and driven down real wages.
The Commerce Department did not immediately respond to a request to comment from the Daily Caller News Foundation.
All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact licensing@dailycallernewsfoundation.org.